Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, Berghoff, Anna Sophie, Furtner, Julia, Marhold, Maximilian, Bergen, Elisabeth Sophie, Roider-Schur, Sophie, Starzer, Angelika Martina, Forstner, Heidrun, Rottenmanner, Beate, Dieckmann, Karin, Bago-Horvath, Zsuzsanna, Haslacher, Helmuth, Widhalm, Georg, Ilhan-Mutlu, Aysegül, Minichsdorfer, Christoph, Fuereder, Thorsten, Szekeres, Thomas, Oehler, Leopold, Gruenberger, Birgit, Singer, Christian F., Weltermann, Ansgar, Puhr, Rainer, Preusser, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499862/
https://www.ncbi.nlm.nih.gov/pubmed/35941372
http://dx.doi.org/10.1038/s41591-022-01935-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499862/
https://www.ncbi.nlm.nih.gov/pubmed/35941372
http://dx.doi.org/10.1038/s41591-022-01935-8

Ejemplares similares